MedTrace Logo

Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

NCT00779337 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2012-05-22

No results posted yet for this study

Summary

This trial will use a new method of treating lymphoma using a therapy derived from a person's Killer T cells. These Killer T cells are taken from a person's blood and grown in a test tube to increase the number of these cells that are specifically active against the lymphoma cells. The cells are then given to the patient by intravenous infusion with the aim of killing the lymphoma cells. Potentially this treatment will help to kill the residual/recurrent tumour that is present after other lymphoma treatment and reduce the chance of the tumour recurring.

Conditions

Interventions

BIOLOGICAL

Autologous AdE1- Latent Membrane Protein CTLs

Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.

Sponsors & Collaborators

  • The Atlantic Philanthropies

    collaborator OTHER

  • Australian Department of Industry, Tourism and Resources

    collaborator INDUSTRY

  • British Society for Haematology

    collaborator OTHER

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Queensland Institute of Medical Research

    lead OTHER

Principal Investigators

  • Maher K Gandhi, MB CHB PhD · Queensland Institute of Medical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2012-01-31
Completion
2012-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00779337 on ClinicalTrials.gov